$HROW

Harrow (NASDAQ:HROW) reported Q2 revenue of $15.6M for IHEEZO, with demand up to 65,477 units (+44% sequential, +34% YoY) but revenue lagging due to distributor sell-through of prior inventory. Management cited normalized channel inventory, ~25% higher net pricing effective July 1, gross margin 71%, and cash of $83.9M. Harrow also discussed BYOOVIZ launch, VEVYE PBM coverage, and a pending TYRVAYA acquisition.

HARROW, INC. (HROW) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 ex99-2.htm EX-99.2 Exhibit 99.2 28 th Quarterly Letter to Stockholders August 10, 2026 Dear Harrow Stockholders: The first half of 2026 was about driving demand and fine-tuning business rules ; the second half is about converting growing demand into revenue and profits

HARROW, INC. (HROW) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001360214 0001360214 2026-08-03 2026-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Harrow (Nasdaq: HROW) announced the U.S. commercial launch of BYOOVIZ (ranibizumab-nuna), an FDA-approved interchangeable biosimilar referencing Lucentis, for wet AMD, RVO macular edema, and mCNV. The launch follows Harrow’s exclusive U.S. commercialization agreement with Samsung Bioepis. Harrow also noted exclusive U.S. rights to OPUVIZ (aflibercept-yszy).

HARROW, INC. (HROW) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001360214 0001360214 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Harrow said it is advancing VERKAZIA, the second of three priority products outlined in its Letter to Stockholders, as part of its ophthalmology portfolio strategy focused on underserved diseases. The company describes VERKAZIA as a topical calcineurin inhibitor for VKC inflammation, citing trials showing improved keratitis and reduced symptoms and corticosteroid rescue use. William Blair said the relaunch may be a supplemental revenue source. Shares were up 3.45% to $35.50 Thursday.

Royce & Associates LP reduced its Harrow, Inc. (NASDAQ:HROW) stake by 4.4% in Q4, selling 23,267 shares to hold 509,746 shares worth about $24.98M, per its SEC disclosure. Harrow reported May 11 EPS of -$0.74 vs -$0.43 consensus and revenue of $44.2M vs $52.43M. Analysts’ average target is $69.43.

An Opaleye-managed account recently sold 5,000 shares of Harrow (HROW) common stock at $54.18 per share on February 27, 2026, as reported in a Form 4 SEC filing. Following this transaction, the managed account holds 65,000 shares, while Opaleye, L.P. directly owns an additional 3,815,000 shares. Opaleye Management Inc. disclaims beneficial ownership beyond its pecuniary interest in these shares.

Harrow, Inc. (HROW) reported record revenues of $272.3 million in 2025, marking a 36% increase, primarily driven by strong growth in branded products. The company also significantly narrowed its net loss to $5.1 million. Strategic moves included the acquisition of Melt Pharmaceuticals, expansion of its branded portfolio, and a complete debt refinancing, positioning HROW for future growth with new product launches and a strong cash reserve.

Harrow, Inc. reported strong financial results for Q4 and full-year 2025, with revenue increasing 36% to $272.3 million for the year. The company provided 2026 guidance, expecting revenue between $350 million and $365 million and Adjusted EBITDA of $80 million to $100 million, driven by the expanding sales teams for key ophthalmic brands VEVYE and TRIESENCE, and the strategic repositioning of IHEEZO. Harrow also highlighted significant progress in its development pipeline, including G-MELT and YOCHIL, reinforcing confidence in its long-term growth strategy.